Literature DB >> 16362383

Antibiotics and gastrointestinal colonization by vancomycin-resistant enterococci.

L B Rice1.   

Abstract

Although several classes of antimicrobial agents have been associated with colonization or infection with glycopeptide-resistant enterococci (GRE) in individual clinical studies, the agents most commonly implicated are extended-spectrum cephalosporins and compounds with potent activity against anaerobic bacteria, including ticarcillin-clavulanic acid. In some clinical studies, formulary alterations designed to minimize the use of extended-spectrum cephalosporins or ticarcillin-clavulanic acid have resulted in significant decreases in colonization and infection by GRE. Experimental data using a mouse model of GRE gastrointestinal colonization indicate that persistence of high-level GRE colonization of the mouse gastrointestinal tract is promoted by exposure to agents with potent activity against anaerobic bacteria, suggesting that reduction of competing flora is the major factor leading to persistence of high-level colonization. One study performed in humans is consistent with this model and suggests that high levels of colonization may promote spread of resistant organisms in the nosocomial setting. Establishing colonization with GRE in uncolonized mice correlates with exposure to agents that are (a) secreted into the bile in significant concentrations and (b) have negligible activity against the colonizing enterococcal strain. Differences between piperacillin-tazobactam and ceftriaxone in the establishment model can be attributed directly to differences in their anti-enterococcal activity. Modification of antimicrobial prescribing practices may play an important role in facilitating successful infection control efforts to limit GRE in the nosocomial setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16362383     DOI: 10.1007/s10096-005-0057-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  66 in total

1.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

2.  Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis.

Authors:  I T Paulsen; L Banerjei; G S A Myers; K E Nelson; R Seshadri; T D Read; D E Fouts; J A Eisen; S R Gill; J F Heidelberg; H Tettelin; R J Dodson; L Umayam; L Brinkac; M Beanan; S Daugherty; R T DeBoy; S Durkin; J Kolonay; R Madupu; W Nelson; J Vamathevan; B Tran; J Upton; T Hansen; J Shetty; H Khouri; T Utterback; D Radune; K A Ketchum; B A Dougherty; C M Fraser
Journal:  Science       Date:  2003-03-28       Impact factor: 47.728

Review 3.  Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals.

Authors:  D M Shlaes; D N Gerding; J F John; W A Craig; D L Bornstein; R A Duncan; M R Eckman; W E Farrer; W H Greene; V Lorian; S Levy; J E McGowan; S M Paul; J Ruskin; F C Tenover; C Watanakunakorn
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

4.  Properties of erythromycin-inducible transposon Tn917 in Streptococcus faecalis.

Authors:  P K Tomich; F Y An; D B Clewell
Journal:  J Bacteriol       Date:  1980-03       Impact factor: 3.490

5.  Patients in long-term care facilities: a reservoir for vancomycin-resistant enterococci.

Authors:  Marnie L Elizaga; Robert A Weinstein; Mary K Hayden
Journal:  Clin Infect Dis       Date:  2002-01-07       Impact factor: 9.079

6.  Comparison of glycopeptide-resistant Enterococcus faecium isolates and glycopeptide resistance genes of human and animal origins.

Authors:  P R Descheemaeker; S Chapelle; L A Devriese; P Butaye; P Vandamme; H Goossens
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

7.  Nosocomial acquisition of beta-lactamase--negative, ampicillin-resistant enterococcus.

Authors:  V A Chirurgi; S E Oster; A A Goldberg; R E McCabe
Journal:  Arch Intern Med       Date:  1992-07

8.  Cephalosporins as risk factor for nosocomial Enterococcus faecalis bacteremia. A matched case-control study.

Authors:  R Pallares; M Pujol; C Peña; J Ariza; R Martin; F Gudiol
Journal:  Arch Intern Med       Date:  1993-07-12

9.  Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures.

Authors:  Alexander A Padiglione; Rory Wolfe; Elizabeth A Grabsch; Di Olden; Stephen Pearson; Clare Franklin; Denis Spelman; Barrie Mayall; Paul D R Johnson; M Lindsay Grayson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant enterococci.

Authors:  L S Chavers; S A Moser; E Funkhouser; W H Benjamin; P Chavers; A M Stamm; K B Waites
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

View more
  6 in total

Review 1.  Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.

Authors:  Louis B Rice
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

Review 2.  The management of infections due to drug-resistant gram-positive bacteria.

Authors:  R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

3.  A mouse model for characterization of gastrointestinal colonization rates among environmental Aeromonas isolates.

Authors:  Dennis J Lye
Journal:  Curr Microbiol       Date:  2009-01-09       Impact factor: 2.188

4.  Production of enterocins L50A, L50B, and IT, a new enterocin, by Enterococcus faecium IT62, a strain isolated from Italian ryegrass in Japan.

Authors:  Esther Izquierdo; Audrey Bednarczyk; Christine Schaeffer; Yimin Cai; Eric Marchioni; Alain Van Dorsselaer; Saïd Ennahar
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

5.  Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.

Authors:  Wanda C Reygaert
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423

6.  Antibiotic Susceptibility Patterns, Biofilm Formation and esp Gene among Clinical Enterococci: Is There Any Association?

Authors:  Poh Leng Weng; Ramliza Ramli; Rukman Awang Hamat
Journal:  Int J Environ Res Public Health       Date:  2019-09-17       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.